AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 10225548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanguinarine toothpaste and oral rinse
Number of subjects: 60
Study 10225548 — intervention group
Group type: COMPARATOR
Intervention: Control toothpaste and oral rinse without sanguinarine
Number of subjects: 60
Study 8942892 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitomycin C (0.5 mg/ml)
Number of subjects: 72
Study 8942892 — intervention group
Group type: COMPARATOR
Intervention: Placebo (balanced salt solution)
Number of subjects: 72
Study 1883776 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.4% Methoxyflurane (MOF)
Number of subjects: 2
Study 1883776 — intervention group
Group type: COMPARATOR
Intervention: Phenol
Number of subjects: 2
Study 1883776 — intervention group
Group type: EXPERIMENTAL
Intervention: Methoxyflurane (MOF)
Number of subjects: 2
Study 7161115 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg of dexamethasone
Number of subjects: 349
Study 7161115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 349
Study 31852676 — intervention group
Group type: EXPERIMENTAL
Intervention: Saying 'Today will be a quiet day'
Number of subjects: 61
Study 31852676 — intervention group
Group type: COMPARATOR
Intervention: Refraining from saying 'quiet'
Number of subjects: 61
Study 27762628 — intervention group
Group type: EXPERIMENTAL
Intervention: 80% power from beginning until the end of treatment
Number of subjects: 320
Study 27762628 — intervention group
Group type: EXPERIMENTAL
Intervention: First 100 shockwaves at 40% power, then 80% power until the end of treatment
Number of subjects: 320
Study 27762628 — intervention group
Group type: EXPERIMENTAL
Intervention: First 100 shocks at 40% power, followed by a 3‐minute pause, then 80% power until the end of treatment
Number of subjects: 320
Study 27762628 — intervention group
Group type: EXPERIMENTAL
Intervention: First 100 shocks at 80% power, followed by a 3‐minute pause, then 80% power until the end of treatment
Number of subjects: 320
Study 27920416 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous pantoprazole 40 mg daily
Number of subjects: 0
Study 27920416 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% NaCl)
Number of subjects: 0
Study 26905705 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (200 mg) followed by vaginal misoprostol induction
Number of subjects: 100
Study 26905705 — intervention group
Group type: COMPARATOR
Intervention: Vaginal misoprostol induction only
Number of subjects: 100
Study 22160450 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil meal
Number of subjects: 40
Study 22160450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cream meal
Number of subjects: 40
Study 22160450 — intervention group
Group type: EXPERIMENTAL
Intervention: Both meals (olive oil and cream)
Number of subjects: 40
Study 22160450 — intervention group
Group type: EXPERIMENTAL
Intervention: Chylomicron-PON1 activity
Number of subjects: 40
Study 21063138 — intervention group
Group type: EXPERIMENTAL
Intervention: Air-abrasion method (KCP 2000 PLUS)
Number of subjects: 88
Study 21063138 — intervention group
Group type: COMPARATOR
Intervention: Acid etching method (Vococid)
Number of subjects: 88
Study 17984842 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg FTY720 (Group 1)
Number of subjects: 271
Study 17984842 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg FTY720 (Group 2)
Number of subjects: 271
Study 17984842 — intervention group
Group type: COMPARATOR
Intervention: mycophenolate mofetil (MMF; Group 3)
Number of subjects: 271
Study 15979438 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-measured minimum stent diameters
Number of subjects: 212
Study 15979438 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted stent diameters from manufacturers' compliance charts
Number of subjects: 212
Study 15979438 — intervention group
Group type: EXPERIMENTAL
Intervention: Ratio of IVUS to predicted diameters
Number of subjects: 212
Study 15979438 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS measurements for different stent sizes
Number of subjects: 212
Study 15979438 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS measurements for different stent manufacturers
Number of subjects: 212
Study 15979438 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of stents achieving predicted diameters
Number of subjects: 212
Study 11960300 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete micronutrient-enriched liquid nutrition supplement (125 ml and 0.6 MJ (135 kcal) twice daily)
Number of subjects: 42
Study 11960300 — intervention group
Group type: COMPARATOR
Intervention: Placebo (twice daily)
Number of subjects: 42
Study 9864279 — intervention group
Group type: EXPERIMENTAL
Intervention: 21 mg/day transdermal nicotine
Number of subjects: 11
Study 9864279 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 mg/day transdermal nicotine
Number of subjects: 11
Study 9864279 — intervention group
Group type: EXPERIMENTAL
Intervention: 63 mg/day transdermal nicotine
Number of subjects: 11
Study 9864279 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 8748047 — intervention group
Group type: EXPERIMENTAL
Intervention: ipsapirone (mean daily dose 19.5 mg)
Number of subjects: 160
Study 8748047 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam (mean daily dose 4.2 mg)
Number of subjects: 160
Study 8748047 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study 2028089 — intervention group
Group type: EXPERIMENTAL
Intervention: Low similarity tasks with contextual interference during acquisition and retention.
Number of subjects: 60
Study 2028089 — intervention group
Group type: EXPERIMENTAL
Intervention: High similarity tasks with contextual interference during acquisition and retention.
Number of subjects: 60
Study 2028089 — intervention group
Group type: EXPERIMENTAL
Intervention: Transfer trials of a novel movement after retention interval.
Number of subjects: 60
Study 6118384 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg nebulized)
Number of subjects: 10
Study 6118384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30608001 — intervention group
Group type: EXPERIMENTAL
Intervention: myo-inositol
Number of subjects: 53
Study 28004320 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive brivaracetam
Number of subjects: 1095
Study 26445141 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (ACS)
Number of subjects: 0
Study 23374201 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week Iyengar yoga program (2 x 90-min classes and 5 x 30-min home sessions per week)
Number of subjects: 42
Study 21340401 — intervention group
Group type: EXPERIMENTAL
Intervention: Human rhinovirus (HRV) detection
Number of subjects: 47
Study 21340401 — intervention group
Group type: EXPERIMENTAL
Intervention: Human metapneumovirus (hMPV) detection
Number of subjects: 47
Study 21340401 — intervention group
Group type: COMPARATOR
Intervention: Influenza A/B and RSV detection
Number of subjects: 47
Study 19729344 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg interferon beta‐1b
Number of subjects: 2244
Study 19729344 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg interferon beta‐1b
Number of subjects: 2244
Study 19729344 — intervention group
Group type: COMPARATOR
Intervention: 20 mg glatiramer acetate
Number of subjects: 2244
Study 17544884 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Number of subjects: 60
Study 17544884 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine
Number of subjects: 60
Study 17544884 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluid
Number of subjects: 60
Study 17544884 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 15383081 — intervention group
Group type: EXPERIMENTAL
Intervention: Single incremental cycle exercise test with respiratory gas exchange measurement.
Number of subjects: 0
Study 15383081 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeatability of the incremental test over 5-6 weeks.
Number of subjects: 0
Study 11685417 — intervention group
Group type: EXPERIMENTAL
Intervention: Magstim 200
Number of subjects: 2
Study 11685417 — intervention group
Group type: EXPERIMENTAL
Intervention: Magstim Super Rapid
Number of subjects: 2
Study 11685417 — intervention group
Group type: COMPARATOR
Intervention: Both stimulators
Number of subjects: 2
Study 9624645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH) conditions at 682 Torr
Number of subjects: 28
Study 9624645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH) conditions at 632 Torr
Number of subjects: 28
Study 9624645 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypobaric hypoxia (HH) conditions at 566 Torr
Number of subjects: 28
Study 8027961 — intervention group
Group type: EXPERIMENTAL
Intervention: Laboratory reactivity tasks (isometric handgrip, mental arithmetic, structured discussion)
Number of subjects: 126
Study 8027961 — intervention group
Group type: EXPERIMENTAL
Intervention: Discussion task
Number of subjects: 126
Study 8027961 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall lab mean for SBP
Number of subjects: 126
Study 8027961 — intervention group
Group type: EXPERIMENTAL
Intervention: Math task
Number of subjects: 126
Study 2512936 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient therapy
Number of subjects: 71
Study 2512936 — intervention group
Group type: COMPARATOR
Intervention: Intensive outpatient therapy
Number of subjects: 71
Study 897965 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus BCG
Number of subjects: 0
Study 897965 — intervention group
Group type: EXPERIMENTAL
Intervention: MTX plus BCG plus INH
Number of subjects: 0
Study 897965 — intervention group
Group type: COMPARATOR
Intervention: MTX alone
Number of subjects: 0
Study 31309699 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg once daily
Number of subjects: 4744
Study 31309699 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 4744
Study 29512795 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitrous oxide (MEOPA)
Number of subjects: 115
Study 29512795 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study 25494860 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction diet alone
Number of subjects: 93
Study 25494860 — intervention group
Group type: EXPERIMENTAL
Intervention: Caloric restriction diet + resistance training
Number of subjects: 93
Study 25494860 — intervention group
Group type: COMPARATOR
Intervention: Control group (caloric restriction diet alone)
Number of subjects: 93
Study 25494860 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 93
Study 22441111 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics supplementation
Number of subjects: 31
Study 22441111 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 21489738 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Intervention (BI)
Number of subjects: 511
Study 21489738 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 511
Study 19298339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactoferrin supplementation
Number of subjects: 1343
Study 19298339 — intervention group
Group type: COMPARATOR
Intervention: No lactoferrin supplementation (Control)
Number of subjects: 1343
Study 17630678 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting with distal emboli protection using the PRECISE Nitinol Stent and the ANGIOGUARD XP Emboli Capture Guidewire
Number of subjects: 1158
Study 17630678 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting with distal emboli protection
Number of subjects: 1158
Study 15111138 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency exercise program (twice daily, including weekends)
Number of subjects: 246
Study 15111138 — intervention group
Group type: COMPARATOR
Intervention: Low frequency exercise program (once daily, not on weekends)
Number of subjects: 246
Study 15111138 — intervention group
Group type: EXPERIMENTAL
Intervention: High frequency exercise program
Number of subjects: 246
Study 15111138 — intervention group
Group type: COMPARATOR
Intervention: Low frequency exercise program
Number of subjects: 246
Study 11676354 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta 5000 IU
Number of subjects: 180
Study 11676354 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin beta 1000 IU
Number of subjects: 180
Study 11676354 — intervention group
Group type: COMPARATOR
Intervention: Best supportive care and blood transfusions (if clinically indicated)
Number of subjects: 180
Study 9054253 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose mivazerol (1.5 micrograms.kg‐1.h‐1)
Number of subjects: 300
Study 9054253 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose mivazerol (0.75 microgram.kg‐1.h‐1)
Number of subjects: 300
Study 9054253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300
Study 7523907 — intervention group
Group type: EXPERIMENTAL
Intervention: TGr mutant T-lymphocytes
Number of subjects: 58
Study 7523907 — intervention group
Group type: EXPERIMENTAL
Intervention: Calculated mutation frequency
Number of subjects: 58
Study 3662745 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (20 mg)
Number of subjects: 34
Study 3662745 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 28770099 — intervention group
Group type: EXPERIMENTAL
Intervention: BRiMS programme plus usual care
Number of subjects: 60
Study 28770099 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 60
Study 27420150 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls Management Exercise (FaME)
Number of subjects: 1256
Study 27420150 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Programme (OEP)
Number of subjects: 1256
Study 27420150 — intervention group
Group type: EXPERIMENTAL
Intervention: Falls Management Exercise (FaME) and Otago Exercise Programme (OEP)
Number of subjects: 1256
Study 26385666 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fluid therapy with supplementary intraoperative stroke volume optimization (mean 956 ml Gelofusine)
Number of subjects: 220
Study 26385666 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid therapy (control group)
Number of subjects: 220
Study 26385666 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard fluid therapy with supplementary intraoperative stroke volume optimization
Number of subjects: 220
Study 24009303 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet (40% of caloric intake; n = 370)
Number of subjects: 738
Study 24009303 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (20% caloric intake; n = 368)
Number of subjects: 738
Study 24009303 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat diet
Number of subjects: 738
Study 24009303 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet
Number of subjects: 738
Study 24009303 — intervention group
Group type: EXPERIMENTAL
Intervention: rs2943641 variant
Number of subjects: 738
Study 21904231 — intervention group
Group type: EXPERIMENTAL
Intervention: 65% 1RM
Number of subjects: 147
Study 21904231 — intervention group
Group type: EXPERIMENTAL
Intervention: 90% 1RM
Number of subjects: 147
Study 18054930 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal estrogen supplementation (100 microg/d)
Number of subjects: 100
Study 18054930 — intervention group
Group type: COMPARATOR
Intervention: No transdermal estrogen supplementation
Number of subjects: 100
Study 16793154 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-fraction radiotherapy (8 Gy x 1)
Number of subjects: 376
Study 16793154 — intervention group
Group type: COMPARATOR
Intervention: Multiple-fraction radiotherapy (3 Gy x 10)
Number of subjects: 376
Study 14575384 — intervention group
Group type: EXPERIMENTAL
Intervention: Taxan combined with carboplatin
Number of subjects: 25
Study 10913925 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate taken 2 hours before breakfast
Number of subjects: 31
Study 10913925 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate taken 1 hour before breakfast
Number of subjects: 31
Study 10913925 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate taken 0.5 hours before breakfast
Number of subjects: 31
Study 10913925 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate taken 2 hours after breakfast
Number of subjects: 31
Study 10913925 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate taken with breakfast
Number of subjects: 31
Study 8818502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast neutron therapy
Number of subjects: 28
Study 8818502 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for primary site recurrence
Number of subjects: 28
Study 8818502 — intervention group
Group type: EXPERIMENTAL
Intervention: Fistula repair
Number of subjects: 28
Study 8818502 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 28
Study 8818502 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment of locoregional recurrence
Number of subjects: 28
Study 1431012 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 60
Study 1431012 — intervention group
Group type: COMPARATOR
Intervention: Mianserin
Number of subjects: 60
Study 3888810 — intervention group
Group type: COMPARATOR
Intervention: Ampicillin-tobramycin
Number of subjects: 73
Study 3888810 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 73
Study 31574261 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1-mL lavender oil diffusion
Number of subjects: 90
Study 31574261 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3-mL lavender oil diffusion
Number of subjects: 90
Study 31574261 — intervention group
Group type: COMPARATOR
Intervention: No oil (control group)
Number of subjects: 90
Study 29424786 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate ART
Number of subjects: 592
Study 29424786 — intervention group
Group type: COMPARATOR
Intervention: Deferred ART
Number of subjects: 592
Study 26779620 — intervention group
Group type: EXPERIMENTAL
Intervention: Spirulina maxima supplementation (2 g daily for 3 months)
Number of subjects: 50
Study 26779620 — intervention group
Group type: COMPARATOR
Intervention: Placebo (2 g daily for 3 months)
Number of subjects: 50
Study 25259745 — intervention group
Group type: EXPERIMENTAL
Intervention: aTRH
Number of subjects: 14864
Study 22648340 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise at three intensities
Number of subjects: 6
Study 22648340 — intervention group
Group type: COMPARATOR
Intervention: Breathing room air at rest
Number of subjects: 6
Study 22648340 — intervention group
Group type: EXPERIMENTAL
Intervention: Breathing 100% oxygen during mild exercise at 63 ± 15 W
Number of subjects: 6
Study 22648340 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise under room air conditions
Number of subjects: 6
Study 22648340 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of mild exercise, hyperventilation, and normobaric hyperoxia (100% oxygen inhalation)
Number of subjects: 6
Study 20117456 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI) with stenting
Number of subjects: 510
Study 20117456 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 510
Study 20117456 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI with stenting
Number of subjects: 510
Study 20117456 — intervention group
Group type: COMPARATOR
Intervention: CABG
Number of subjects: 510
Study 20117456 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (subset of PCI patients)
Number of subjects: 510
Study 18003938 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 18003938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no CEL subgroup)
Number of subjects: 65
Study 18003938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low CEL subgroup)
Number of subjects: 65
Study 18003938 — intervention group
Group type: COMPARATOR
Intervention: Placebo (high CEL subgroup)
Number of subjects: 65
Study 16631880 — intervention group
Group type: EXPERIMENTAL
Intervention: bivalent HPV‐16/18 virus‐like particle AS04 vaccine
Number of subjects: 776
Study 16631880 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 776
Study 14725411 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc supplementation (10 mg elemental zinc as zinc sulphate)
Number of subjects: 300
Study 14725411 — intervention group
Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 300
Study 11083892 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta agonist treatment
Number of subjects: 50
Study 11083892 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone treatment
Number of subjects: 50
Study 11083892 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment for pneumothorax
Number of subjects: 50
Study 11083892 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment for chylous effusions
Number of subjects: 50
Study 11083892 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening for renal angiomyolipoma by CT scanning
Number of subjects: 50
Study 11083892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregnancy after diagnosis
Number of subjects: 50
Study 8823238 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan plus nitroglycerin
Number of subjects: 10
Study 8823238 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus nitroglycerin
Number of subjects: 10
Study 1728708 — intervention group
Group type: EXPERIMENTAL
Intervention: Diclofenac, 75 mg intramuscularly twice daily
Number of subjects: 44
Study 6428590 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (non‐halogenated glucocorticoid) administered by nasal inhaler
Number of subjects: 0
Study 6428590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6428590 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide
Number of subjects: 0
Study 30530637 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital video intervention watched by parents in intervention clinics
Number of subjects: 1596
Study 30530637 — intervention group
Group type: COMPARATOR
Intervention: Control clinic (no intervention)
Number of subjects: 1596
Study 30530637 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents watched the video
Number of subjects: 1596